PER2 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant PER2.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, IF, E |
---|---|
Primary Accession | O15055 |
Other Accession | NM_022817 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Isotype | IgG2b Kappa |
Clone Names | 5C10 |
Calculated MW | 136579 Da |
Gene ID | 8864 |
---|---|
Other Names | Period circadian protein homolog 2, hPER2, Circadian clock protein PERIOD 2, PER2, KIAA0347 |
Target/Specificity | PER2 (NP_073728, 1 a.a. ~ 100 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | PER2 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene is a member of the Period family of genes and is expressed in a circadian pattern in the suprachiasmatic nucleus, the primary circadian pacemaker in the mammalian brain. Genes in this family encode components of the circadian rhythms of locomotor activity, metabolism, and behavior. Circadian expression in the suprachiasmatic nucleus continues in constant darkness, and a shift in the light/dark cycle evokes a proportional shift of gene expression in the suprachiasmatic nucleus. The specific function of this gene is not yet known.
References
1.Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer.Zhao H, Zeng ZL, Yang J, Jin Y, Qiu MZ, Hu XY, Han J, Liu KY, Liao JW, Xu RH, Zou QF.Int J Clin Exp Pathol. 2014 Jan 15;7(2):619-30.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.